The Dual Roles of Regulatory B Cells in Infection, Cancer, and Immunity

Abstract

Regulatory B cells (Bregs) are a functionally defined yet phenotypically heterogeneous subset of lymphocytes that are essential for maintaining immune homeostasis. Their canonical function is regulated through the secretion of interleukin-10 (IL-10), a potent anti-inflammatory cytokine. However, accumulating evidence indicates that other molecules, such as IL-35 and transforming growth factor-β, and that of contact-dependent pathways, such as Programmed Cell Death Ligand-1 (PD-L1) and Programmed Cell Death-1 (PD-1), also play indispensable roles in their regulatory arsenal. This review examines the immunoregulatory roles of Bregs across diverse clinical contexts, including infectious diseases, cancers, autoimmune disorders (such as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and uveitis), and organ transplantation. Crucially, we highlight a fundamental functional dichotomy: although Bregs confer protection against autoimmunity and promote transplant tolerance, they concurrently drive the progression of chronic infections and malignancies by dampening antipathogen and antitumor immune responses. This functional dichotomy highlights the complexity of immune regulation, where Bregs act as critical nodes balancing health and pathology. The immense therapeutic potential by modulating Bregs activity and unresolved questions that will guide the future frontiers of Bregs research are essentially discussed.

Keywords

chronic infections / IL-10 / regulatory B cells / tumor-related immunity

References

[1] L. Mesin, J. Ersching, and G. D. Victora, “Germinal center B cell dynamics,” Immunity 45, no. 3 (2016): 471–482.

[2] R. Wang, C. Lan, K. Benlagha, et al., “The Interaction of Innate Immune and Adaptive Immune System,” MedComm 5, no. 10 (2024): e714.

[3] S. I. Katz, D. Parker, and J. L. Turk, “B-cell Suppression of Delayed Hypersensitivity Reactions,” Nature 251, no. 5475 (1974): 550–551.

[4] C. Mauri and A. Bosma, “Immune Regulatory Function of B Cells,” Annual Review of Immunology 30, no. 1 (2012): 221–241.

[5] A. Mizoguchi, E. Mizoguchi, H. Takedatsu, R. S. Blumberg, and A. K. Bhan, “Chronic Intestinal Inflammatory Condition Generates IL-10-producing Regulatory B Cell Subset Characterized by CD1d Upregulation,” Immunity 16, no. 2 (2002): 219–230.

[6] I. Abeles, C. Palma, N. Meednu, A. S. Payne, R. J. Looney, and J. H. Anolik, “B Cell-directed Therapy in Autoimmunity,” Annual Review of Immunology 42, no. 1 (2024): 103–126.

[7] S. Dass, E. M. Vital, and P. Emery, “Development of Psoriasis After B Cell Depletion With rituximab,” Arthritis and Rheumatism 56, no. 8 (2007): 2715–2718.

[8] M. Goetz, R. Atreya, M. Ghalibafian, P. R. Galle, and M. F. Neurath, “Exacerbation of Ulcerative Colitis After rituximab Salvage Therapy,” Inflammatory Bowel Diseases 13, no. 11 (2007): 1365–1368.

[9] S. Zhang, Z. Ouyang, Z. Fan, et al., “T Cell-specific Deficiency of Src Homology 2-containing Protein Tyrosine Phosphatase 2 Ameliorates Psoriasis and Colitis by Promoting Treg Differentiation,” MedComm 6, no. 8 (2025): e70310.

[10] S. Hori, T. Nomura, and S. Sakaguchi, “Control of Regulatory T Cell Development by the Transcription Factor Foxp3,” Science 299, no. 5609 (2003): 1057–1061.

[11] J. D. Fontenot, M. A. Gavin, and A. Y. Rudensky, “Foxp3 programs the Development and Function of CD4⁺CD25⁺ Regulatory T Cells,” Nature Immunology 4, no. 4 (2003): 330–336.

[12] H. Moreira, A. Dobosz, Ł. Cwynar-Zając, et al., “Unraveling the Role of Breg Cells in Digestive Tract Cancer and Infectious Immunity,” Frontiers in Immunology 13 (2022): 981847.

[13] D. Catalán, M. A. Mansilla, A. Ferrier, et al., “Immunosuppressive Mechanisms of Regulatory B Cells,” Frontiers in Immunology 12 (2021): 611795.

[14] J. Gallego-Valle, V. A. Pérez-Fernández, R. Correa-Rocha, and M. Pion, “Generation of human Breg-Like Phenotype With Regulatory Function in Vitro With Bacteria-derived Oligodeoxynucleotides,” International Journal of Molecular Sciences 19, no. 6 (2018): 1737.

[15] J. Choi, P. S. C. Leung, C. Bowlus, and M. E. Gershwin, “IL-35 and Autoimmunity: A Comprehensive Perspective,” Clinical Reviews in Allergy & Immunology 49, no. 3 (2015): 327–332.

[16] M. Wang, Z. Gu, J. Yang, H. Zhao, and Z. Cao, “Changes Among TGF-β1⁺ Breg Cells and Helper T Cell Subsets in a Murine Model of Allergic Rhinitis With Prolonged OVA Challenge,” International Immunopharmacology 69 (2019): 347–357.

[17] G. Carvajal Alegria, D. Cornec, A. Saraux, et al., “Abatacept Promotes Regulatory B Cell Functions, Enhancing Their Ability to Reduce the Th1 Response in Rheumatoid Arthritis Patients Through the Production of IL-10 and TGF-β,” Journal of Immunology 207, no. 2 (2021): 470–482.

[18] N. Petriv, H. Suo, I. Hochnadel, et al., “Essential Roles of B Cell Subsets in the Progression of MASLD and HCC,” JHEP Reports 6, no. 12 (2024): 101189.

[19] A. R. Khan, E. Hams, A. Floudas, T. Sparwasser, C. T. Weaver, and P. G. Fallon, “PD-L1^hi B Cells Are Critical Regulators of Humoral Immunity,” Nature Communications 6, no. 1 (2015): 5997.

[20] A. G. Loxton and I. C. van Rensburg, “FasL Regulatory B-cells During Mycobacterium Tuberculosis Infection and TB Disease,” Journal of Molecular Biology 433, no. 13 (2021): 166984.

[21] J. M. Lykken, K. M. Candando, and T. F. Tedder, “Regulatory B10 Cell Development and Function,” International Immunology 27, no. 10 (2015): 471–477.

[22] T. Matsushita and T. F. Tedder, “Identifying Regulatory B Cells (B10 cells) That Produce IL-10 in mice,” in Suppression and Regulation of Immune Responses, ed. MC Cuturi and I Anegon (Methods in Molecular Biology. Humana Press, 2010), 99–111.

[23] T. Matsushita, K. Yanaba, J. D. Bouaziz, M. Fujimoto, and T. F. Tedder, “Regulatory B Cells Inhibit EAE Initiation in Mice While Other B Cells Promote Disease Progression,” Journal of Clinical Investigation 118, no. 10 (2008): 3420–3430.

[24] Y. J. Jung, J. S. Woo, S. H. Hwang, et al., “Effect of IL-10-producing B Cells in Peripheral Blood and Tumor Tissue on Gastric Cancer,” Cell Communication and Signaling 21, no. 1 (2023): 320.

[25] K. Yanaba, J. D. Bouaziz, T. Matsushita, T. Tsubata, and T. F. Tedder, “The Development and Function of Regulatory B Cells Expressing IL-10 (B10 cells) Requires Antigen Receptor Diversity and TLR Signals,” Journal of Immunology 182, no. 12 (2009): 7459–7472.

[26] Y. Iwata, T. Matsushita, M. Horikawa, et al., “Characterization of a Rare IL-10-competent B-cell Subset in Humans That Parallels Mouse Regulatory B10 Cells,” Blood 117, no. 2 (2011): 530–541.

[27] E. C. Rosser, K. Oleinika, S. Tonon, et al., “Regulatory B Cells Are Induced by Gut Microbiota–driven Interleukin-1β and Interleukin-6 Production,” Nature Medicine 20, no. 11 (2014): 1334–1339.

[28] J. G. Evans, K. A. Chavez-Rueda, A. Eddaoudi, et al., “Novel Suppressive Function of Transitional 2 B Cells in Experimental Arthritis,” Journal of Immunology 178, no. 12 (2007): 7868–7878.

[29] A. Cherukuri, K. Mohib, and D. M. Rothstein, “Regulatory B Cells: TIM-1, Transplant Tolerance, and Rejection,” Immunological Reviews 299, no. 1 (2021): 31–44.

[30] X. Tian, X. Zheng, and D. Tian, “B-cell Immune Checkpoint TIM-1: A Potential Target for Tumour Immunotherapy,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 389.

[31] Q. Ding, M. Yeung, G. Camirand, et al., “Regulatory B Cells Are Identified by Expression of TIM-1 and Can be Induced Through TIM-1 Ligation to Promote Tolerance in Mice,” Journal of Clinical Investigation 121, no. 9 (2011): 3645–3656.

[32] F. Flores-Borja, A. Bosma, D. Ng, et al., “CD19⁺ CD24^hi CD38^hi B cells maintain regulatory T cells while limiting Th1 and Th17 differentiation,” Science Translational Medicine 5, no. 173 (2013): 173ra23.

[33] P. A. Blair, L. Y. Noreña, F. Flores-Borja, et al., “CD19(+)CD24(hi)CD38(hi) B Cells Exhibit Regulatory Capacity in Healthy Individuals but Are Functionally Impaired in Systemic Lupus Erythematosus Patients,” Immunity 32, no. 1 (2010): 129–140.

[34] T. Li, Z. Yu, Z. Qu, N. Zhang, R. Crew, and Y. Jiang, “Decreased Number of CD19⁺CD24^hiCD38^hi Regulatory B Cells in Diabetic Nephropathy,” Molecular Immunology 112 (2019): 233–239.

[35] S. Kleffel, A. Vergani, S. Tezza, et al., “Interleukin-10⁺ Regulatory B Cells Arise Within Antigen-experienced CD40⁺ B Cells to Maintain Tolerance to Islet Autoantigens,” Diabetes 64, no. 1 (2015): 158–171.

[36] B. Yang, X. Tan, X. Xiong, et al., “Effect of CD40/CD40L Signaling on IL-10-producing Regulatory B Cells in chinese Children With henoch-schönlein purpura Nephritis,” Immunologic Research 65, no. 3 (2017): 592–604.

[37] W. van de Veen, B. Stanic, G. Yaman, et al., “IgG4 production Is Confined to human IL-10-producing Regulatory B Cells That Suppress Antigen-specific Immune Responses,” Journal of Allergy and Clinical Immunology 131, no. 4 (2013): 1204–1212.

[38] S. Lindner, K. Dahlke, K. Sontheimer, et al., “Interleukin 21-induced Granzyme B-expressing B Cells Infiltrate Tumors and Regulate T Cells,” Cancer Research 73, no. 8 (2013): 2468–2479.

[39] T. Matsushita, M. Horikawa, Y. Iwata, and T. F. Tedder, “Regulatory B Cells (B10 cells) and Regulatory T Cells Have Independent Roles in Controlling Experimental Autoimmune Encephalomyelitis Initiation and Late-phase Immunopathogenesis,” Journal of Immunology 185, no. 4 (2010): 2240–2252.

[40] K. Yanaba, J. D. Bouaziz, K. M. Haas, J. C. Poe, M. Fujimoto, and T. F. Tedder, “A Regulatory B Cell Subset With a Unique CD1d^hiCD5⁺ Phenotype Controls T Cell-dependent Inflammatory Responses,” Immunity 28, no. 5 (2008): 639–650.

[41] M. Matsumoto, A. Baba, T. Yokota, et al., “Interleukin-10-producing Plasmablasts Exert Regulatory Function in Autoimmune Inflammation,” Immunity 41, no. 6 (2014): 1040–1051.

[42] N. Eiza, E. Zuckerman, M. Carlebach, T. Rainis, Y. Goldberg, and Z. Vadasz, “Increased Killer B Cells in Chronic HCV Infection May Lead to Autoimmunity and Increased Viral Load,” Clinical and Experimental Immunology 193, no. 2 (2018): 183–193.

[43] R. Bankoti, K. Gupta, A. Levchenko, and S. Stäger, “Marginal Zone B Cells Regulate Antigen-specific T Cell Responses During Infection,” Journal of Immunology 188, no. 8 (2012): 3961–3971.

[44] S. Xiao, C. R. Brooks, R. A. Sobel, and V. K. Kuchroo, “Tim-1 Is Essential for Induction and Maintenance of IL-10 in Regulatory B Cells and Their Regulation of Tissue Inflammation,” Journal of Immunology 194, no. 4 (2015): 1602–1608.

[45] F. Tian, Y. Jiao, B. Yang, et al., “Dynamics and MicroRNA144/451-mediated Mechanisms of Regulatory B Cells During Schistosoma Japonicum Infection in Mice,” Acta Tropica 272 (2025): 107912.

[46] H. Guan, J. Peng, L. Jiang, G. Mo, X. Li, and X. Peng, “CD19⁺CD1d^hiCD5^hi B cells can downregulate malaria ITV protection by IL-10 secretion,” Front Public Health 8 (2020): 77.

[47] X. Han, J. Yang, Y. Zhang, et al., “Potential Role for Regulatory B Cells as a Major Source of Interleukin-10 in Spleen From Plasmodium chabaudi-infected Mice,” Infection and Immunity 86, no. 5 (2018): e00016–18.

[48] P. Shen, T. Roch, V. Lampropoulou, et al., “IL-35-producing B Cells Are Critical Regulators of Immunity During Autoimmune and Infectious Diseases,” Nature 507, no. 7492 (2014): 366–370.

[49] R. X. Wang, C. R. Yu, I. M. Dambuza, et al., “Interleukin-35 Induces Regulatory B Cells That Suppress Autoimmune Disease,” Nature Medicine 20, no. 6 (2014): 633–641.

[50] J. K. Choi, C. R. Yu, S. J. Bing, et al., “IL-27–producing B-1a Cells Suppress Neuroinflammation and CNS Autoimmune Diseases,” Proceedings of the National Academy of Sciences of the United States of America 118, no. 47 (2021): e2109548118.

[51] A. Das, G. Ellis, C. Pallant, et al., “IL-10-producing Regulatory B Cells in the Pathogenesis of Chronic hepatitis B Virus Infection,” Journal of Immunology 189, no. 8 (2012): 3925–3935.

[52] Y. Wang, Y. Qin, X. Wang, et al., “Decrease in the Proportion of CD24hi CD38hi B Cells and Impairment of Their Regulatory Capacity in Type 1 Diabetes Patients,” Clinical and Experimental Immunology 200, no. 1 (2020): 22–32.

[53] Y. Jiao, X. Wang, T. Zhang, et al., “Regulatory B Cells Correlate With HIV Disease Progression,” Microbiology and Immunology 58, no. 8 (2014): 449–455.

[54] E. Garner-Spitzer, A. Wagner, M. Paulke-Korinek, et al., “Tick-borne Encephalitis (TBE) and hepatitis B Nonresponders Feature Different Immunologic Mechanisms in Response to TBE and Influenza Vaccination With Involvement of Regulatory T and B Cells and IL-10,” Journal of Immunology 191, no. 5 (2013): 2426–2436.

[55] X. Zhang, R. Gilbert, R. Sampson, O. Tomkins-Netzer, V. Calder, and S. Lightman, “CD19⁺CD24^hiCD38^hi B regulatory cell levels correlate with disease remission in patients with non-infectious uveitis,” Investigative Ophthalmology & Visual Science 59, no. 9 (2018): 2523.

[56] J. F. Varghese, B. J. Kaskow, F. von Glehn, et al., “Human Regulatory Memory B Cells Defined by Expression of TIM-1 and TIGIT Are Dysfunctional in Multiple Sclerosis,” Frontiers in Immunology 15 (2024): 1360219.

[57] M. Zhang, G. Zeng, Q. Yang, et al., “Anti-tuberculosis Treatment Enhances the Production of IL-22 Through Reducing the Frequencies of Regulatory B Cell,” Tuberculosis 94, no. 3 (2014): 238–244.

[58] Z. Ye, Y. Jiang, D. Sun, W. Zhong, L. Zhao, and Z. Jiang, “The Plasma Interleukin (IL)-35 Level and Frequency of Circulating IL-35⁺ Regulatory B Cells Are Decreased in a Cohort of chinese Patients With New-onset Systemic Lupus Erythematosus,” Scientific Reports 9, no. 1 (2019): 13210.

[59] Z. Jiang, H. Zhu, P. Wang, et al., “Different Subpopulations of Regulatory T Cells in human Autoimmune Disease, Transplantation, and Tumor Immunity,” MedComm 3, no. 2 (2022): e137.

[60] L. I. Sakkas, “Regulatory B Cells in Autoimmune Rheumatic Diseases,” Mediterranean Journal of Rheumatology 28, no. 2 (2017): 75–79.

[61] L. M. Williams, G. Ricchetti, U. Sarma, T. Smallie, and B. M. J. Foxwell, “Interleukin-10 Suppression of Myeloid Cell Activation — a Continuing Puzzle,” Immunology 113, no. 3 (2004): 281–292.

[62] R. de Waal Malefyt, J. Abrams, B. Bennett, C. G. Figdor, and J. E. de Vries, “Interleukin 10(IL-10) Inhibits Cytokine Synthesis by human Monocytes: An Autoregulatory Role of IL-10 Produced by Monocytes,” Journal of Experimental Medicine 174, no. 5 (1991): 1209–1220.

[63] J. M. McBride, T. Jung, J. E. de Vries, and G. Aversa, “IL-10 Alters DC Function via Modulation of Cell Surface Molecules Resulting in Impaired T-cell Responses,” Cellular Immunology 215, no. 2 (2002): 162–172.

[64] S. K. Mittal, K. J. Cho, S. Ishido, and P. A. Roche, “Interleukin 10 (IL-10)-mediated Immunosuppression: MARCH-I INDUCTION REGULATES ANTIGEN PRESENTATION by MACROPHAGES but NOT DENDRITIC CELLS,” Journal of Biological Chemistry 290, no. 45 (2015): 27158–27167.

[65] H. Groux, A. O'Garra, and M. Bigler, “A CD4⁺ T-cell Subset Inhibits Antigen-specific T-cell Responses and Prevents Colitis,” Nature 389, no. 6652 (1997): 737–742.

[66] C. H. Chien and B. L. Chiang, “Regulatory T Cells Induced by B Cells: A Novel Subpopulation of Regulatory T Cells,” Journal of Biomedical Science 24 (2017): 86.

[67] Y. Lu, F. Liu, C. Li, Y. Chen, D. Weng, and J. Chen, “IL-10-producing B Cells Suppress Effector T Cells Activation and Promote Regulatory T Cells in Crystalline Silica-induced Inflammatory Response in Vitro,” Mediators Inflammation 2017 (2017): 8415094.

[68] K. M. Lee, Q. Fu, G. Huai, et al., “Suppression of Allograft Rejection by Regulatory B Cells Induced via TLR Signaling,” JCI Insight 7, no. 17 (2022): e152213.

[69] K. Jansen, L. Cevhertas, S. Ma, P. Satitsuksanoa, M. Akdis, and W. van de Veen, “Regulatory B cells, a to Z,” Allergy 76, no. 9 (2021): 2699–2715.

[70] J. Zhang, Y. Zhang, Q. Wang, et al., “Interleukin-35 in Immune-related Diseases: Protection or Destruction,” Immunology 157, no. 1 (2019): 13–20.

[71] A. Huang, L. Cheng, M. He, J. Nie, J. Wang, and K. Jiang, “Interleukin-35 on B Cell and T Cell Induction and Regulation,” Journal of inflammation (London, England) 14 (2017): 16.

[72] W. Zysk, J. Gleń, and M. Trzeciak, “Current Insight Into the Role of IL-35 and Its Potential Involvement in the Pathogenesis and Therapy of Atopic Dermatitis,” International Journal of Molecular Sciences 23, no. 24 (2022): 15709.

[73] J. K. Choi and C. E. Egwuagu, “Interleukin 35 Regulatory B Cells,” Journal of Molecular Biology 433, no. 1 (2021): 166607.

[74] D. A. A. Vignali and V. K. Kuchroo, “IL-12 family Cytokines: Immunological Playmakers,” Nature Immunology 13, no. 8 (2012): 722–728.

[75] C. Pot, L. Apetoh, A. Awasthi, and V. K. Kuchroo, “Induction of Regulatory Tr1 Cells and Inhibition of TH17 Cells by IL-27,” Seminars in Immunology 23, no. 6 (2011): 438–445.

[76] W. P. Chong, N. van Panhuys, J. Chen, et al., “NK-DC Crosstalk Controls the Autopathogenic Th17 Response Through an Innate IFN-γ-IL-27 Axis,” Journal of Experimental Medicine 212, no. 10 (2015): 1739–1752.

[77] S. Wu, R. Ma, Y. Zhong, et al., “Deficiency of IL-27 Signaling Exacerbates Experimental Autoimmune Uveitis With Elevated Uveitogenic Th1 and Th17 Responses,” International Journal of Molecular Sciences 22, no. 14 (2021): 7517.

[78] M. Kang, M. K. Yadav, E. C. Mbanefo, C. R. Yu, and C. E. Egwuagu, “IL-27-containing Exosomes Secreted by Innate B-1a Cells Suppress and Ameliorate Uveitis,” Frontiers in Immunology 14 (2023): 1071162.

[79] M. O. Li, Y. Y. Wan, S. Sanjabi, A. K. L. Robertson, and R. A. Flavell, “Transforming Growth Factor-beta Regulation of Immune Responses,” Annual Review of Immunology 24 (2006): 99–146.

[80] K. Bjarnadóttir, M. Benkhoucha, D. Merkler, et al., “B Cell-derived Transforming Growth Factor-β1 Expression Limits the Induction Phase of Autoimmune Neuroinflammation,” Scientific Reports 6 (2016): 34594.

[81] H. Huang, Z. Wang, Y. Zhang, et al., “Mesothelial Cell-derived Antigen-presenting Cancer-associated Fibroblasts Induce Expansion of Regulatory T Cells in Pancreatic Cancer,” Cancer Cell 40, no. 6 (2022): 656–673.e7.

[82] O. Palomares, M. Martín-Fontecha, R. Lauener, et al., “Regulatory T Cells and Immune Regulation of Allergic Diseases: Roles of IL-10 and TGF-β,” Genes and Immunity 15, no. 8 (2014): 511–520.

[83] C. Sun, R. Mezzadra, and T. N. Schumacher, “Regulation and Function of the PD-L1 Checkpoint,” Immunity 48, no. 3 (2018): 434–452.

[84] G. J. Freeman, A. J. Long, Y. Iwai, et al., “Engagement of the PD-1 Immunoinhibitory Receptor by a Novel B7 family Member Leads to Negative Regulation of Lymphocyte Activation,” Journal of Experimental Medicine 192, no. 7 (2000): 1027–1034.

[85] W. Chen, X. Ning, Y. Liu, et al., “Myeloid-derived Suppressor Cells From Tumour-bearing Mice Induce the Population Expansion of CD19hiFcγRIIbhi Regulatory B Cells via PD-L1,” Immunology 172, no. 1 (2024): 127–143.

[86] X. Xiao, X. M. Lao, M. M. Chen, et al., “PD-1hi Identifies a Novel Regulatory B-cell Population in human Hepatoma That Promotes Disease Progression,” Cancer Discovery 6, no. 5 (2016): 546–559.

[87] B. Siewe, J. T. Stapleton, J. Martinson, et al., “Regulatory B Cell Frequency Correlates With Markers of HIV Disease Progression and Attenuates Anti-HIV CD8⁺ T Cell Function in Vitro,” Journal of Leukocyte Biology 93, no. 5 (2013): 811–818.

[88] A. J. Patel, Z. N. Willsmore, N. Khan, et al., “Regulatory B Cell Repertoire Defects Predispose Lung Cancer Patients to Immune-related Toxicity Following Checkpoint Blockade,” Nature Communications 13, no. 1 (2022): 3148.

[89] K. Wang, L. Tao, J. Su, et al., “TLR4 supports the Expansion of FasL⁺CD5⁺CD1dhi Regulatory B Cells, Which Decreases in Contact Hypersensitivity,” Molecular Immunology 87 (2017): 188–199.

[90] M. W. Klinker, T. J. Reed, D. A. Fox, and S. K. Lundy, “Interleukin-5 Supports the Expansion of Fas Ligand-expressing Killer B Cells That Induce Antigen-specific Apoptosis of CD4⁺ T Cells and Secrete Interleukin-10,” PLoS ONE 8, no. 8 (2013): e70131.

[91] S. K. Lundy and D. A. Fox, “Reduced Fas Ligand-expressing Splenic CD5⁺ B Lymphocytes in Severe Collagen-induced Arthritis,” Arthritis Research & Therapy 11, no. 4 (2009): R128.

[92] R. Thompson and X. Cao, “Reassessing Granzyme B: Unveiling Perforin-independent Versatility in Immune Responses and Therapeutic Potentials,” Frontiers in Immunology 15 (2024): 1392535.

[93] F. Figueiró, L. Muller, S. Funk, E. K. Jackson, A. M. O. Battastini, and T. L. Whiteside, “Phenotypic and Functional Characteristics of CD39^high human Regulatory B Cells (Breg),” Oncoimmunology 5, no. 2 (2016): e1082703.

[94] Z. Saze, P. J. Schuler, C. S. Hong, D. Cheng, E. K. Jackson, and T. L. Whiteside, “Adenosine Production by human B Cells and B Cell-mediated Suppression of Activated T Cells,” Blood 122, no. 1 (2013): 9–18.

[95] I. Ludwig-Portugall and L. E. Layland, “TLRs, Treg, and B Cells, an Interplay of Regulation During Helminth Infection,” Frontiers in Immunology 3 (2012): 8.

[96] M. A. M. Chayé, T. A. Gasan, A. Ozir-Fazalalikhan, et al., “Schistosoma mansoni Egg-derived Thioredoxin and Sm14 Drive the Development of IL-10 Producing Regulatory B Cells,” PLOS Neglected Tropical Diseases 17, no. 6 (2023): e0011344.

[97] S. Haeberlein, K. Obieglo, A. Ozir-Fazalalikhan, et al., “Schistosome Egg Antigens, Including the Glycoprotein IPSE/Alpha-1, Trigger the Development of Regulatory B Cells,” Plos Pathogens 13, no. 7 (2017): e1006539.

[98] F. Tian, X. Hu, K. Xian, et al., “B10 cells Induced by Schistosoma japonicum Soluble Egg Antigens Modulated Regulatory T cells and Cytokine Production of T cells,” Parasitology Research 114, no. 10 (2015): 3827–3834.

[99] S. Amu, S. P. Saunders, M. Kronenberg, N. E. Mangan, A. Atzberger, and P. G. Fallon, “Regulatory B Cells Prevent and Reverse Allergic Airway Inflammation via FoxP3-positive T Regulatory Cells in a Murine Model,” Journal of Allergy and Clinical Immunology 125, no. 5 (2010): 1114–1124.e8.

[100] L. van der Vlugt, J. F. Zinsou, A. Ozir-Fazalalikhan, et al., “Interleukin 10 (IL-10)-producing CD1dhi Regulatory B Cells From Schistosoma Haematobium-infected Individuals Induce IL-10-positive T Cells and Suppress Effector T-cell Cytokines,” Journal of Infectious Diseases 210, no. 8 (2014): 1207–1216.

[101] J. Xiao, F. Guan, L. Sun, et al., “B cells induced by Schistosoma japonicum infection display diverse regulatory phenotypes and modulate CD4⁺ T cell response,” Parasites Vectors 13, no. 1 (2020): 147.

[102] L. van der Vlugt, L. A. Labuda, A. Ozir-Fazalalikhan, et al., “Schistosomes Induce Regulatory Features in human and Mouse CD1d(hi) B Cells: Inhibition of Allergic Inflammation by IL-10 and Regulatory T Cells,” PLoS ONE 7, no. 2 (2012): e30883.

[103] R. G. Schaut, I. M. Lamb, A. J. Toepp, et al., “Regulatory IgDhi B Cells Suppress T Cell Function via IL-10 and PD-L1 During Progressive Visceral Leishmaniasis,” Journal of Immunology 196, no. 10 (2016): 4100–4109.

[104] C. Ronet, Y. Hauyon-La Torre, M. Revaz-Breton, et al., “Regulatory B Cells Shape the Development of Th2 Immune Responses in BALB/c Mice Infected With Leishmania Major Through IL-10 Production,” Journal of Immunology 184, no. 2 (2010): 886–894.

[105] G. Andreani, M. Ouellet, R. Menasria, A. M. Gomez, C. Barat, and M. J. Tremblay, “Leishmania Infantum Amastigotes Trigger a Subpopulation of human B Cells With an Immunoregulatory Phenotype,” PLOS Neglected Tropical Diseases 9, no. 2 (2015): e0003543.

[106] Q. Li, T. Liu, K. Lv, et al., “Malaria: Past, Present, and Future,” Signal Transduction and Targeted Therapy 10, no. 1 (2025): 188.

[107] M. Kalkal and J. Das, “Current Understanding of the Immune Potential of B-cell Subsets in Malarial Pathogenesis,” Frontiers in Microbiology 14 (2023): 1046002.

[108] Y. Liu, Y. Chen, Z. Li, et al., “Role of IL-10-producing Regulatory B Cells in Control of Cerebral Malaria in Plasmodium berghei Infected Mice,” European Journal of Immunology 43, no. 11 (2013): 2907–2918.

[109] C. Gutiérrez, J. Lopez-Abente, V. Pérez-Fernández, et al., “Analysis of the Dysregulation Between Regulatory B and T Cells (Breg and Treg) in human Immunodeficiency Virus (HIV)-infected Patients,” PLoS ONE 14, no. 3 (2019): e0213744.

[110] Y. Liu, L. S. Cheng, S. D. Wu, et al., “IL-10-producing Regulatory B-cells Suppressed Effector T-cells but Enhanced Regulatory T-cells in Chronic HBV Infection,” Clinical Science 130, no. 11 (2016): 907–919.

[111] L. Wang, J. Qiu, L. Yu, X. Hu, P. Zhao, and Y. Jiang, “Increased Numbers of CD5⁺CD19⁺CD1d^highIL-10⁺ Bregs, CD4⁺Foxp3⁺ Tregs, CD4⁺CXCR5⁺Foxp3⁺ Follicular Regulatory T (TFR) Cells in CHB or CHC Patients,” Journal of Translational Medicine 12 (2014): 251.

[112] M. Liu, H. Y. Chen, L. Luo, et al., “Neutralization of IL-10 Produced by B Cells Promotes Protective Immunity During Persistent HCV Infection in Humanized Mice,” European Journal of Immunology 50, no. 9 (2020): 1350–1361.

[113] K. Doyon-Laliberté, M. Aranguren, J. Poudrier, and M. Roger, “Marginal Zone B-cell Populations and Their Regulatory Potential in the Context of HIV and Other Chronic Inflammatory Conditions,” International Journal of Molecular Sciences 23, no. 6 (2022): 3372.

[114] M. Aranguren, K. Doyon-Laliberté, M. El-Far, et al., “Subclinical Atherosclerosis Is Associated With Discrepancies in BAFF and April Levels and Altered Breg Potential of Precursor-Like Marginal Zone B-cells in Long-term HIV Treated Individuals,” Vaccines 11, no. 1 (2022): 81.

[115] B. Siewe, J. Wallace, S. Rygielski, et al., “Regulatory B Cells Inhibit Cytotoxic T Lymphocyte (CTL) Activity and Elimination of Infected CD4 T Cells After in Vitro Reactivation of HIV Latent Reservoirs,” PLoS ONE 9, no. 4 (2014): e92934.

[116] V. Tabanelli, V. Santiago-Pacheco, M. Corbellino, et al., “Cytotoxic epstein-barr Virus-positive Large B Cell Lymphoma: A Regulatory B Cell-derived Neoplasia?,” Histopathology 70, no. 4 (2017): 650–656.

[117] J. Liu, W. Zhan, C. J. Kim, et al., “IL-10-producing B Cells Are Induced Early in HIV-1 Infection and Suppress HIV-1-specific T Cell Responses,” PLoS ONE 9, no. 2 (2014): e89236.

[118] G. Wang, Y. Liu, R. Huang, et al., “Characteristics of Regulatory B Cells in Patients With Chronic hepatitis B Virus Infection in Different Immune Phases,” Discovery Medicine 23, no. 128 (2017): 295–304.

[119] Y. Gong, C. Zhao, P. Zhao, et al., “Role of IL-10-producing Regulatory B Cells in Chronic hepatitis B Virus Infection,” Digestive Diseases and Sciences 60, no. 5 (2015): 1308–1314.

[120] X. Jin, Z. H. Yan, L. Lu, S. Lu, G. Zhang, and W. Lin, “Peripheral Immune Cells Exhaustion and Functional Impairment in Patients With Chronic hepatitis B,” Frontiers in Medicine 8 (2021): 759292.

[121] N. Alatrakchi, “Bregs in Chronic HBV: Is It Time for Bragging Rights?,” Digestive Diseases and Sciences 60, no. 5 (2015): 1115–1117.

[122] Y. Liu, Y. Luo, T. Zhu, et al., “Regulatory B Cells Dysregulated T Cell Function in an IL-35-dependent Way in Patients With Chronic hepatitis B,” Frontiers in Immunology 12 (2021): 653198.

[123] R. Wang, R. Xie, and Z. Song, “Circulating Regulatory Tfh Cells Are Enriched in Patients With Chronic hepatitis B Infection and Induce the Differentiation of Regulatory B Cells,” Experimental Cell Research 365, no. 2 (2018): 171–176.

[124] J. Lopez-Abente, A. Prieto-Sanchez, M. Á. Muñoz-Fernandez, R. Correa-Rocha, and M. Pion, “Human Immunodeficiency Virus Type-1 Induces a Regulatory B Cell-Like Phenotype in Vitro,” Cellular & Molecular Immunology 15, no. 10 (2018): 917–933.

[125] D. Laubreton, C. Drajac, J. F. Eléouët, et al., “Regulatory B Lymphocytes Colonize the respiratory Tract of Neonatal Mice and Modulate Immune Responses of Alveolar Macrophages to RSV Infection in IL-10-dependant Manner,” Viruses 12, no. 8 (2020): 822.

[126] D. Zhivaki, S. Lemoine, A. Lim, et al., “Respiratory Syncytial Virus Infects Regulatory B Cells in human Neonates via Chemokine Receptor CX3CR1 and Promotes Lung Disease Severity,” Immunity 46, no. 2 (2017): 301–314.

[127] D. Damjanovic, C. L. Small, M. Jeyanathan, S. McCormick, and Z. Xing, “Immunopathology in Influenza Virus Infection: Uncoupling the Friend From Foe,” Clinical Immunology 144, no. 1 (2012): 57–69.

[128] V. Upasani, I. Rodenhuis-Zybert, and T. Cantaert, “Antibody-independent Functions of B Cells During Viral Infections,” Plos Pathogens 17, no. 7 (2021): e1009708.

[129] J. Yu, V. H. H. Duong, K. Westphal, et al., “Surface Receptor Toso Controls B Cell–mediated Regulation of T Cell Immunity,” Journal of Clinical Investigation 128, no. 5 (2018): 1820–1836.

[130] J. H. Lam and N. Baumgarth, “The Multifaceted B Cell Response to Influenza Virus,” Journal of Immunology 202, no. 2 (2019): 351–359.

[131] X. Dong, H. Tu, S. Qin, X. Bai, F. Yang, and Z. Li, “Insights Into the Roles of B Cells in Patients With Sepsis,” Journal of Immunology Research 2023 (2023): 7408967.

[132] L. Tao, Y. Wang, J. Xu, et al., “IL-10-producing Regulatory B Cells Exhibit Functional Defects and Play a Protective Role in Severe Endotoxic Shock,” Pharmacological Research 148 (2019): 104457.

[133] M. Aziz, Y. Ode, M. Zhou, et al., “B-1a Cells Protect Mice From Sepsis-induced Acute Lung Injury,” Molecular Medicine 24, no. 1 (2018): 26.

[134] E. Guirado and L. S. Schlesinger, “Modeling the Mycobacterium Tuberculosis Granuloma-the Critical Battlefield in Host Immunity and Disease,” Frontiers in Immunology 4 (2013): 98.

[135] J. Y. Phuah, J. T. Mattila, P. L. Lin, and J. L. Flynn, “Activated B Cells in the Granulomas of Nonhuman Primates Infected With Mycobacterium Tuberculosis,” American Journal of Pathology 181, no. 2 (2012): 508–514.

[136] R. V. Swanson, A. Gupta, T. W. Foreman, et al., “Antigen-specific B Cells Direct T Follicular-Like Helper Cells Into Lymphoid Follicles to Mediate Mycobacterium Tuberculosis Control,” Nature Immunology 24, no. 5 (2023): 855–868.

[137] C. Yuan, Z. L. Qu, X. L. Tang, et al., “Mycobacterium tuberculosis mannose-capped lipoarabinomannan induces IL-10-producing B cells and hinders CD4⁺Th1 immunity,” iScience 11 (2019): 13–30.

[138] M. Zhang, X. Zheng, J. Zhang, et al., “CD19(+)CD1d(+)CD5(+) B Cell Frequencies Are Increased in Patients With Tuberculosis and Suppress Th17 Responses,” Cellular Immunology 274, no. 1-2 (2012): 89–97.

[139] Y. C. Dai, W. D. Wang, J. A. Zhang, et al., “MTB Driven B Cells Producing IL-35 and Secreting High Level of IL-10 in the Patients With Active Pulmonary Tuberculosis,” Molecular Immunology 112 (2019): 175–181.

[140] T. Girma, A. Tsegaye, K. Desta, et al., “Phenotypic Characterization of Peripheral B Cells in Mycobacterium Tuberculosis Infection and Disease in Addis Ababa, Ethiopia,” Tuberculosis 140 (2023): 102329.

[141] A. J. Griffin and S. J. McSorley, “Development of Protective Immunity to Salmonella, a Mucosal Pathogen With a Systemic Agenda,” Mucosal Immunology 4, no. 4 (2011): 371–382.

[142] L. B. Luis, G. T. Ana, G. E. Carlos, et al., “Salmonella Promotes Its Own Survival in B Cells by Inhibiting Autophagy,” Cells 11, no. 13 (2022): 2061.

[143] P. Neves, V. Lampropoulou, E. Calderon-Gomez, et al., “Signaling via the MyD88 Adaptor Protein in B Cells Suppresses Protective Immunity During Salmonella Typhimurium Infection,” Immunity 33, no. 5 (2010): 777–790.

[144] S. Fatima, “Tumor Microenvironment: A Complex Landscape of Cancer Development and Drug Resistance,” Cureus 17, no. 4 (2025): e82090.

[145] J. Shang, H. Zha, and Y. Sun, “Phenotypes, Functions, and Clinical Relevance of Regulatory B Cells in Cancer,” Frontiers in Immunology 11 (2020): 582657.

[146] D. Michaud, C. R. Steward, B. Mirlekar, and Y. Pylayeva-Gupta, “Regulatory B Cells in Cancer,” Immunological Reviews 299, no. 1 (2021): 74–92.

[147] Z. Chen, Y. Zhu, R. Du, et al., “Role of Regulatory B Cells in the Progression of Cervical Cancer,” Mediators of Inflammation 2019 (2019): 6519427.

[148] T. Kobayashi, K. Oishi, A. Okamura, et al., “Regulatory B1a Cells Suppress Melanoma Tumor Immunity via IL-10 Production and Inhibiting T Helper Type 1 Cytokine Production in Tumor-infiltrating CD8⁺ T Cells,” Journal of Investigative Dermatology 139, no. 7 (2019): 1535–1544.e1.

[149] S. Shah, A. A. Divekar, S. P. Hilchey, et al., “Increased Rejection of Primary Tumors in Mice Lacking B Cells: Inhibition of Anti-tumor CTL and TH1 Cytokine Responses by B Cells,” International Journal of Cancer 117, no. 4 (2005): 574–586.

[150] H. T. Hu, X. Ai, M. Lu, Z. Song, and H. Li, “Characterization of Intratumoral and Circulating IL-10-producing B Cells in Gastric Cancer,” Experimental Cell Research 384, no. 2 (2019): 111652.

[151] S. Li, B. Mirlekar, B. M. Johnson, et al., “STING-induced Regulatory B Cells Compromise NK Function in Cancer Immunity,” Nature 610, no. 7931 (2022): 373–380.

[152] K. Wang, J. Liu, and J. Li, “IL-35-producing B Cells in Gastric Cancer Patients,” Medicine (Baltimore) 97, no. 19 (2018): e0710.

[153] X. Wang, G. Wang, Z. Wang, et al., “PD-1-expressing B Cells Suppress CD4⁺ and CD8⁺ T Cells via PD-1/PD-L1-dependent Pathway,” Molecular Immunology 109 (2019): 20–26.

[154] C. Yang, Y. Zhang, R. Wang, B. Cheng, Y. Wu, and X. Fu, “IL-10⁺CD19⁺ Regulatory B Cells Induce CD4⁺Foxp3⁺Regulatory T Cells in Serum of Cervical Cancer Patients,” Autoimmunity 57, no. 1 (2024): 2290909.

[155] S. Hao, X. Chen, F. Wang, et al., “Breast Cancer Cell-derived IL-35 Promotes Tumor Progression via Induction of IL-35-producing Induced Regulatory T Cells,” Carcinogenesis 39, no. 12 (2018): 1488–1496.

[156] T. Hu, J. Zhai, Z. Yang, et al., “Myeloid-derived Suppressor Cells in Cancer: Mechanistic Insights and Targeted Therapeutic Innovations,” MedComm 6, no. 6 (2025): e70231.

[157] G. Wei, B. Li, M. Huang, et al., “Polarization of Tumor Cells and Tumor-associated Macrophages: Molecular Mechanisms and Therapeutic Targets,” MedComm 6, no. 9 (2025): e70372.

[158] P. B. Olkhanud, B. Damdinsuren, M. Bodogai, et al., “Tumor-evoked Regulatory B Cells Promote Breast Cancer Metastasis by Converting Resting CD4⁺ T Cells to T-regulatory Cells,” Cancer Research 71, no. 10 (2011): 3505–3515.

[159] Y. Zhang, R. Morgan, C. Chen, et al., “Mammary-tumor-educated B Cells Acquire LAP/TGF-β and PD-L1 Expression and Suppress Anti-tumor Immune Responses,” International Immunology 28, no. 9 (2016): 423–433.

[160] Z. Y. Xu-Monette, J. Zhou, and K. H. Young, “PD-1 Expression and Clinical PD-1 Blockade in B-cell Lymphomas,” Blood 131, no. 1 (2018): 68–83.

[161] R. Tan, M. Nie, and W. Long, “The Role of B Cells in Cancer Development,” Frontiers in Oncology 12 (2022): 958756.

[162] X. Song, H. Liang, F. Nan, et al., “Autoimmune Diseases: Molecular Pathogenesis and Therapeutic Targets,” MedComm 6, no. 7 (2025): e70262.

[163] S. Fillatreau, C. H. Sweenie, M. J. McGeachy, D. Gray, and S. M. Anderton, “B Cells Regulate Autoimmunity by Provision of IL-10,” Nature Immunology 3, no. 10 (2002): 944–950.

[164] Y. Atisha-Fregoso, B. Toz, and B. Diamond, “Meant to B: B Cells as a Therapeutic Target in Systemic Lupus erythematosus,” Journal of Clinical Investigation 131, no. 12 (2021): e149095.

[165] I. Sanz and F. E. H. Lee, “B Cells as Therapeutic Targets in SLE,” Nature Reviews Rheumatology 6, no. 6 (2010): 326–337.

[166] S. Fillatreau, B. Manfroi, and T. Dörner, “Toll-Like Receptor Signalling in B Cells During Systemic Lupus Erythematosus,” Nature Reviews Rheumatology 17, no. 2 (2021): 98–108.

[167] K. Heinemann, B. Wilde, A. Hoerning, et al., “Decreased IL-10(+) Regulatory B Cells (Bregs) in Lupus Nephritis Patients,” Scandinavian Journal of Rheumatology 45, no. 4 (2016): 312–316.

[168] J. Kosałka-Węgiel, B. Jakieła, R. Dziedzic, et al., “Circulating B Lymphocyte Subsets in Patients with Systemic Lupus Erythematosus,” Medicina (Kaunas) 60, no. 12 (2024): 1994.

[169] M. R. Boulassel, A. Al-Naamani, A. Al-Zubaidi, et al., “Coexistence of Sickle Cell Disease and Systemic Lupus Erythematosus Is Associated With Quantitative and Qualitative Impairments in Circulating Regulatory B Cells,” Human Immunology 83, no. 12 (2022): 818–825.

[170] Z. Z. Zhu, X. H. Chen, S. R. Wei, et al., “Role of CD19⁺ CD5⁺ CD1d⁺ Bregs in Maintaining the Th17/Treg Balance in Mice With Systemic Lupus Erythematosus Complicated With Atherosclerosis,” International Journal of Rheumatic Diseases 26, no. 6 (2023): 1048–1057.

[171] X. Cai, X. Li, X. Lin, et al., “[expression of Regulatory B Cells in Peripheral Blood of Patients With Systemic Lupus Erythematosus],” Zhonghua Yi Xue Za Zhi 95, no. 17 (2015): 1310–1313.

[172] C. Mauri and M. Menon, “The Expanding family of Regulatory B Cells,” International Immunology 27, no. 10 (2015): 479–486.

[173] M. H. Smith and J. R. Berman, “What Is Rheumatoid Arthritis?,” Jama 327, no. 12 (2022): 1194.

[174] D. Ummarino, “Rheumatoid Arthritis: Defective IL-10-producing Breg Cells,” Nature Reviews Rheumatology 13, no. 3 (2017): 132.

[175] Y. Guo, X. Zhang, M. Qin, and X. Wang, “Changes in Peripheral CD19(+)Foxp3(+) and CD19(+)TGFβ(+) Regulatory B Cell Populations in Rheumatoid Arthritis Patients With Interstitial Lung Disease,” Journal of Thoracic Disease 7, no. 3 (2015): 471–477.

[176] P. Fortea-Gordo, A. Villalba, L. Nuño, et al., “Circulating CD19⁺CD24^hiCD38^hi Regulatory B Cells as Biomarkers of Response to Methotrexate in Early Rheumatoid Arthritis,” Rheumatology (Oxford) 59, no. 10 (2020): 3081–3091.

[177] L. Chen, J. Xu, B. Sun, X. Hong, D. Liu, and H. Li, “The Vital Role of CD19⁺CD24^hiCD38^hi Regulatory B Cells in Rheumatoid Arthritis: Correlations With Disease Activity and Treatment Response,” Advances in Rheumatology 65, no. 1 (2025): 43.

[178] X. Guo, T. Xu, J. Zheng, et al., “Accumulation of Synovial Fluid CD19⁺CD24^hiCD27⁺ B Cells Was Associated With Bone Destruction in Rheumatoid Arthritis,” Scientific Reports 10, no. 1 (2020): 14386.

[179] S. Salomon, C. Guignant, P. Morel, et al., “Th17 and CD24^hiCD27⁺ Regulatory B Lymphocytes Are Biomarkers of Response to Biologics in Rheumatoid Arthritis,” Arthritis Research & Therapy 19, no. 1 (2017): 33.

[180] J. Luo, Q. Y. Su, Q. Li, et al., “POS0455 the Status of Breg Cells and Breg-related Cytokines in Patients With Rheumatoid Arthritis,” Annals of the Rheumatic Diseases 82 (2023): 484–485.

[181] Z. Bankó, J. Pozsgay, D. Szili, et al., “Induction and Differentiation of IL-10-producing Regulatory B Cells From Healthy Blood Donors and Rheumatoid Arthritis Patients,” Journal of Immunology 198, no. 4 (2017): 1512–1520.

[182] B. Owens, “Multiple Sclerosis,” Nature 540, no. 7631 (2016): S1.

[183] H. Asashima, P. P. Axisa, T. H. G. Pham, et al., “Impaired TIGIT Expression on B Cells Drives Circulating Follicular Helper T Cell Expansion in Multiple Sclerosis,” Journal of Clinical Investigation 132, no. 20: e156254.

[184] S. Glatigny and E. Bettelli, “Experimental autoimmune encephalomyelitis (EAE) as animal models of multiple sclerosis (MS),” Cold Spring Harbor Perspectives in Medicine 8, no. 11 (2018): a028977.

[185] A. Pennati, S. Ng, Y. Wu, et al., “Regulatory B Cells Induce Formation of IL-10-expressing T Cells in Mice With Autoimmune Neuroinflammation,” Journal of Neuroscience 36, no. 50 (2016): 12598–12610.

[186] M. Rafei, J. Hsieh, S. Zehntner, et al., “A Granulocyte-macrophage Colony–stimulating Factor and Interleukin-15 Fusokine Induces a Regulatory B Cell Population With Immune Suppressive Properties,” Nature Medicine 15, no. 9 (2009): 1038–1045, Published online 2009.

[187] B. M. Burkholder and D. A. Jabs, “Uveitis for the Non-ophthalmologist,” Bmj 372 (2021): m4979.

[188] F. O. Oladipupo, C. R. Yu, E. Olumuyide, Y. Jittaysothorn, J. K. Choi, and C. E. Egwuagu, “STAT3 deficiency in B Cells Exacerbates Uveitis by Promoting Expansion of Pathogenic Lymphocytes and Suppressing Regulatory B Cells (Bregs) and Tregs,” Scientific Reports 10, no. 1 (2020): 16188.

[189] C. Yu, I. M. Dambuza, S. H. Kim, R. M. Mahdi, and C. Egwuagu, “Suppression of Experimental Autoimmune Uveitis (EAU) and Recovery From Uveitis Correlate With Expansion of Regulatory B Cells (Breg),” Investigative Ophthalmology & Visual Science 55, no. 13 (2014): 2493.

[190] J. K. Choi and C. E. Egwuagu, “Analysis of Regulatory B Cells in Experimental Autoimmune Uveitis,” Methods in Molecular Biology 2270 (2021): 437–450.

[191] T. Wang, Y. Mei, and Z. Li, “Research Progress on Regulatory B Cells in Systemic Lupus Erythematosus,” BioMed Research International 2019 (2019): 7948687.

[192] L. Dubouchet, H. Todorov, R. Seurinck, et al., “Operational Tolerance After Hematopoietic Stem Cell Transplantation Is Characterized by Distinct Transcriptional, Phenotypic, and Metabolic Signatures,” Science Translational Medicine 14, no. 633 (2022): eabg3083.

[193] G. Orlando, S. Soker, and K. Wood, “Operational Tolerance After Liver Transplantation,” Journal of Hepatology 50, no. 6 (2009): 1247–1257.

[194] J. Bigot, C. Pilon, M. Matignon, et al., “Transcriptomic Signature of the CD24hi CD38hi Transitional B Cells Associated with an Immunoregulatory Phenotype in Renal Transplant Recipients,” American Journal of Transplantation 16, no. 12 (2016): 3430–3442.

[195] C. Morath, A. Schmitt, C. Kleist, et al., “Phase I Trial of Donor-derived Modified Immune Cell Infusion in Kidney Transplantation,” Journal of Clinical Investigation 130, no. 5 (2020): 2364–2376.

[196] I. Latorre, A. Esteve-Sole, D. Redondo, et al., “Calcineurin and mTOR Inhibitors Have Opposing Effects on Regulatory T Cells While Reducing Regulatory B Cell Populations in Kidney Transplant Recipients,” Transplant Immunology 35 (2016): 1–6.

[197] M. C. Glass, D. R. Glass, J. P. Oliveria, et al., “Human IL-10-producing B Cells Have Diverse States That Are Induced From Multiple B Cell Subsets,” Cell Reports 39, no. 3 (2022): 110728.

[198] M. Chesneau, A. Pallier, F. Braza, et al., “Unique B Cell Differentiation Profile in Tolerant Kidney Transplant Patients,” American Journal of Transplantation 14, no. 1 (2014): 144–155.

[199] K. M. Lee, R. T. Stott, G. Zhao, et al., “TGF-β-producing Regulatory B Cells Induce Regulatory T Cells and Promote Transplantation Tolerance,” European Journal of Immunology 44, no. 6 (2014): 1728–1736.

[200] R. Y. Alhabbab, E. Nova-Lamperti, O. Aravena, et al., “Regulatory B Cells: Development, Phenotypes, Functions, and Role in Transplantation,” Immunological Reviews 292, no. 1 (2019): 164–179.

[201] S. Shankar, J. Stolp, S. C. Juvet, et al., “Ex Vivo-expanded human CD19⁺TIM-1⁺ Regulatory B Cells Suppress Immune Responses in Vivo and Are Dependent Upon the TIM-1/STAT3 Axis,” Nature Communications 13, no. 1 (2022): 3121.

[202] S. G. Yi, A. O. Gaber, and W. Chen, “B-cell Response in Solid Organ Transplantation,” Frontiers in Immunology 13 (2022): 895157.

[203] Z. Cai and L. Xie, “Regulatory B Cells in Tumor Microenvironment,” Current Issues in Molecular Biology 48, no. 1 (2026): 106.

[204] Y. He, H. Qian, Y. Liu, L. Duan, Y. Li, and G. Shi, “The Roles of Regulatory B Cells in Cancer,” Journal of Immunology Research 2014 (2014): 215471.

[205] M. Schwartz, Y. Zhang, and J. D. Rosenblatt, “B Cell Regulation of the Anti-tumor Response and Role in Carcinogenesis,” Journal for ImmunoTherapy of Cancer 4 (2016): 40.

[206] L. Luo, Q. Liu, S. Peng, et al., “The Number of Regulatory B Cells Is Increased in Mice With Collagen-induced Arthritis,” Open Life Sciences 14 (2019): 12–18.

[207] J. Furuzawa-Carballeda, G. Lima, P. Simancas, et al., “Peripheral Regulatory Cells Immunophenotyping in Kidney Transplant Recipients With Different Clinical Profiles: A Cross-sectional Study,” J Transplant 2012 (2012): 256960.

[208] S. Yu, M. Zhang, Z. Dou, and J. Lu, “Regulatory B Cells: Synergistic Cellular Mechanisms and Therapeutic Potential for Alleviating Transplant Rejection,” Transplant Immunology 92 (2025): 102277.

[209] C. Wang, H. Xu, R. Gao, et al., “CD19⁺CD24^hiCD38^hi regulatory B cells deficiency revealed severity and poor prognosis in patients with sepsis,” BMC Immunology [Electronic Resource] 23, no. 1 (2022): 54.

[210] P. Liu, Z. Xiao, X. Lu, X. Zhang, and J. Huang, “Regulatory B Cells Attenuate Sepsis-associated Pancreatic Injury by Regulating T Cell Homeostasis,” Scientific Reports 15, no. 1 (2025): 14424.

[211] C. Daien, J. Tan, R. Audo, J. Mielle, and L. Macia, “Op0131 gut Derived Acetate Promotes Regulatory b Cells With Anti-inflammatory Effects,” Annals of the Rheumatic Diseases 79 (2020): 85.

[212] W. Li, D. Wang, R. Yue, et al., “Gut Microbes Enlarged the Protective Effect of Transplanted Regulatory B Cells on Rejection of Cardiac Allografts,” Journal of Heart and Lung Transplantation 40, no. 12 (2021): 1502–1516.

[213] S. L. Gupta, N. Khan, S. Basu, and V. Soni, “B-cell-based Immunotherapy: A Promising New Alternative,” Vaccines 10, no. 6 (2022): 879.

[214] B. S. Liu, Y. Cao, T. W. Huizinga, D. A. Hafler, and R. E. M. Toes, “TLR-mediated STAT3 and ERK Activation Controls IL-10 Secretion by human B Cells,” European Journal of Immunology 44, no. 7 (2014): 2121–2129.

[215] Y. Xu, K. Wu, S. Han, et al., “Astilbin Combined With Lipopolysaccharide Induces IL-10-producing Regulatory B Cells via the STAT3 Signalling Pathway,” Biomedicine & Pharmacotherapy 129 (2020): 110450.

[216] E. A. Zheremyan, A. S. Ustiugova, A. N. Uvarova, et al., “Differentially Activated B Cells Develop Regulatory Phenotype and Show Varying Immunosuppressive Features: A Comparative Study,” Frontiers in Immunology 14 (2023): 1178445.

[217] Y. Shao, C. M. Lo, C. C. Ling, et al., “Regulatory B Cells Accelerate Hepatocellular Carcinoma Progression via CD40/CD154 Signaling Pathway,” Cancer Letters 355, no. 2 (2014): 264–272.

[218] A. McNee, A. Kannan, P. Jull, and S. Shankar, “Expanding human Breg for Cellular Therapy in Transplantation: Time for Translation,” Transplantation 109, no. 6 (2025): 926–937.

[219] N. Honke, T. Lowin, B. Opgenoorth, et al., “Endogenously Produced Catecholamines Improve the Regulatory Function of TLR9-activated B Cells,” Plos Biology 20, no. 1 (2022): e3001513.

Rights & permissions

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.